ICYMI: A pharma-backed biotech just went public — priced cautiously #Biotech #IPO
@quartzmedia.bsky.social
@quartzmedia.bsky.social
@drtimos.bsky.socialSignal or noise? > Optogenetic Therapy Could Restore Some Visual Function in
Blindness - Technology Networks >> Comment below! #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #competitivemarketing
@laborjournal.bsky.socialVom Börsengang zum endgültigen Aus: Nach 20 Jahren ist Schluss für das österreichische #Biotech -Unternehmen Marinomed. Trotz Rotalgen-Nasensprays und millionenschwerer Umsätze blieb der wirtschaftliche Erfolg aus. Die Geschichte einer Insolvenz: 👉 www.laborjournal.de/editorials/3...
@nextlogic-ai.bsky.social🎨 New Post: Bioelectronics: How Printed Circuits on Living Tissue Will Reshape Healthcare and Your Career
#ai #biotech #electronics #...
👇 View Full Illustration:
https://nextlogic-ai.achlabo.com/en/bioelectronics-how-printed-circuits-on-living-tissue-will-reshape-healthcare-and-your-career/
@thedailyfathom.bsky.socialBIOTECH · GSK taps AI startup Chai Discovery to design biologics
GSK is expanding its work with Chai Discovery after the AI startup's protein designs worked in GSK's own lab tests, with no target-specific training.
@discoveripo.bsky.socialnews reports say CITY THERAPEUTICS, INC. is expected to list on October 12, 2026
City Therapeutics, Inc. is expected to list on October 12, 2026, as reported by news sources. The biotech company focuses on RNA interference…
Biotech
#IPO #Biotech #PharmaceuticalPreparations #UnitedStates #IPONews
@quartzmedia.bsky.socialThe biotech betting gene-silencing can prevent strokes goes public #Biotech #GeneSilencing
@discoveripo.bsky.socialBirchBioMed Inc. filed for an IPO
BirchBioMed Inc. has filed for an IPO. The Canadian biotech firm focuses on treatments for scarring and autoimmune diseases, developing technologies for conditions…
Biotech
#IPO #Biotech #PharmaceuticalPreparations #Canada #IPONews #pharmaceuticals #clinicalstage
@drtimos.bsky.socialSignal or noise? > Health Rounds: Blindness treatment based on Nobel-winning
research shows promise - WTVB >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #pharmaceutical #biotech
@aspenbio.bsky.socialWhich San Diego biotechs are tackling cancer and expanding? Pharm2Market’s Biotech Hub brings you regional news, events, and venture capital trends. Perfect for founders, sales reps & job hunters! #Biotech #News #Intelligence 🌟
Got questions? Pharm2Market has the answers!
bit.ly/3UfeaSG
@markfortner.bsky.socialWhich San Diego biotechs are tackling cancer and expanding? Pharm2Market’s Biotech Hub brings you regional news, events, and venture capital trends. Perfect for founders, sales reps & job hunters! #Biotech #News #Intelligence 🌟
Got questions? Pharm2Market has the answers!
bit.ly/3UfeaSG
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
@newsramp.comOnco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech
@newsramp.comOnco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) debuts on U.S. markets with its precision 'AND-gated' BiTAC cancer platform, early preclinical proof of concept, $27.5M in financing, and two key executive hires. A Swiss biotech to watch. #Oncology #Biotech
@newsramp.comLantern Pharma (NASDAQ: LTRN) receives USPTO Notice of Allowance for LP-284 blood cancer treatment patent, extending IP protection through 2042. The AI-developed therapy targets mantle cell lymphoma and double-hit lymphoma. #Oncology #Biotech
@newsramp.comLantern Pharma (NASDAQ: LTRN) receives USPTO Notice of Allowance for LP-284 blood cancer treatment patent, extending IP protection through 2042. The AI-developed therapy targets mantle cell lymphoma and double-hit lymphoma. #Oncology #Biotech
@newsramp.comNutriband (NASDAQ: NTRB) confirms its 910,904 outstanding warrants expire Sept. 30, 2026 at $6.43/share — no extension or repricing. That's nearly $5.86M in potential proceeds if fully exercised. Warrant holders should act before the deadline. #NTRB #Biotech
@newsramp.comNutriband (NASDAQ: NTRB) confirms its 910,904 outstanding warrants expire Sept. 30, 2026 at $6.43/share — no extension or repricing. That's nearly $5.86M in potential proceeds if fully exercised. Warrant holders should act before the deadline. #NTRB #Biotech